J&J clot fighter battles Pfizer/Bristol for warfarin switches in red-hot market share race

The market-share gap between next-gen anticoagulants Xarelto and Eliquis has never been smaller--and with a high percentage of patients still turning to old-guard therapy warfarin, it’s anyone’s race.

In its Q3 earnings presentation, Johnson & Johnson rolled out a graph of total prescription share that showed Bristol-Myers Squibb and Pfizer's Eliquis steadily gaining on its own market leader, Xarelto.

The way J&J sees it, there’s still a lot of room out there to grow its blockbuster, because about 54% of patients are still using the older, less-convenient med warfarin, J&J said during its presentation. There's reason for that, J&J acknowledged; unlike warfarin, whose blood-thinning effect is easily countered with vitamin K therapy, the crop of new-age meds--save Boehringer Ingelheim’s third-place Pradaxa--has no reversal agent to stop severe bleeding in an emergency.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

But the next-gen drugs have other advantages, and Pfizer and Bristol know those warfarin patients are there for the taking--and the partners aren’t planning to let J&J run away with all the conversions. After getting off to a brutally slow start, Eliquis has picked up the pace on the back of increased marketing spend, and earlier this year BMS claimed it had a future market leader on its hands.

Johnson & Johnson doesn’t sound worried about its rival’s steady rise, though. Its own market share ticked up to 17.5% in Q3, a 1.7-point increase over the same period last year. And the pharma giant still boasts the largest clinical trial program of the group; it’s conducting 10 trials with new indications or label expansions in mind, spanning conditions including heart failure, embolic stroke and coronary artery disease.

Those new line extensions are no small deal, J&J’s worldwide pharmaceuticals chairman, Joaquin Duato, told investors on the company’s Q3 conference call. The extensions for Xarelto--combined with those planned for Type 2 diabetes med Invokana--“have the potential to drive $3 billion to $5 billion in incremental sales for the cardiovascular franchise,” he said.

Related Articles:
BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa
Bristol-Myers immunotherapies soar, but Eliquis haul tops the charts
Boehringer looks for Pradaxa boost from now FDA-approved antidote
J&J-Bayer and Pfizer-BMS look for advantages in real-world Xarelto, Eliquis data
How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says
BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.